Abstract: The present invention describes 4,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3-amine (EB1), or a pharmaceutically acceptable salt thereof, as a selective MNK inhibitor for use in the treatment of cancers of an hormone-dependent organs, including triple-negative breast cancer, prostate cancer and other referable cancers with p-eIF4E overexpression due to increased MNK activity. The invention also includes particular therapeutic combinations including the 4,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3-amine.

Abstract: The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the compound of formula (I). The present invention further relates to new compounds which are dimers of compounds of formula (I).

Abstract: The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the compound of formula (I). The present invention further relates to new compounds which are dimers of compounds of formula (I).

Abstract: The present invention relates to caffeine for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising caffeine for use in the treatment of myotonic dystrophy type 1 and type 2.

Abstract: The present invention is related to 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, to the preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in the treatment and/or prevention of a non-Hodgkin's lymphoma.

Abstract: The present invention is related to 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, to the preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in the treatment and/or prevention of a non-Hodgkin's lymphoma.

Abstract: The invention comprises compounds which are derived from a drug or a substance with therapeutic properties, and useful as reagents for the synthesis of biostable polymers including said drug in their backbone, namely polyurethanes, polyureas or polyurea urethanes that are biocompatible and biostable. The invention also comprises the processes for preparing the compounds and the polymers, and to the use of these polymers for the manufacture of medical devices.

Abstract: It comprises compounds which are derived from a drug or a substance with therapeutic properties, and useful as reagents for the synthesis of biostable polymers including said drug in their backbone, namely polyurethanes, polyureas or polyurea urethanes that are biocompatible and biostable. It also comprises the processes for preparing the compounds and the polymers, as well as to the use of these polymers for the manufacture of medical devices.

Abstract: The present invention describes the synthesis of the compounds of formulae (1), (2) and (3) in which m and n, which may be identical or different, may have the values 0, 2, 3, 4, 5 and 6; Z and Y, which may be identical or different, represent a nitrogenated cyclic system bonded by nitrogen or by one of the ring carbons or an NR1R2 system; and X is selected from the group consisting of hydrogen, C1-C12 alkyl, substituted alkyl, C3-C12 aryl, amino, alkylamino, nitro, hydroxy, alkoxy, halogen, carboxy or carboxamido. The use of the compounds of formulae (1), (2) and (3) as anti-HIV agents in the treatment of Acquired Immune Deficiency Syndrome (AIDS) is described.

Abstract: This process is intended to obtain clarithromycin. According to the process, it starts from the erythromycin A 9-oxime hydrochloride, which is transformed into clarithromycin by means of a synthetic sequence in which an acetal of the 9-oxime is initially formed. The use of the oxime hydrochloride permits that only the use of catalytic amounts of pyridine salts are necessary to favor the reaction. Next, the hydroxyls in positions 2′ and 4″ are protected with a silylating agent and the hydroxyl in position 6 is methylated; all this without the isolation of any reaction intermediate being necessary. Finally, the acetal and 2′ and 4″ silanes unprotection, followed by the deoximation yields clarithromycin with a high yield and a form which is easily applicable industrially.

Abstract: This process is intended to obtain clarithromycin. According to the process, it starts from the erythromycin A 9-oxime hydrochloride, which is transformed into clarithromycin by means of a synthetic sequence in which an acetal of the 9-oxime is initially formed. The use of the oxime hydrochloride permits that only the use of catalytic amounts of pyridine salts are necessary to favor the reaction. Next, the hydroxyls in positions 2′ and 4″ are protected with a silylating agent and the hydroxyl in position 6 is methylated; all this without the isolation of any reaction intermediate being necessary. Finally, the acetal and 2′ and 4″ silanes unprotection, followed by the deoximation yields clarithromycin with a high yield and a form which is easily applicable industrially.